Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 1:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 170 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Adult Female Participants Clear all
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Astaxanthin in Healthy Participants

NCT05376501
View directory record Official record
Conditions
Healthy
Interventions
Astaxanthin, Placebo
Dietary Supplement · Other
Lead sponsor
LycoRed Ltd.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 9, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants

NCT06775730
View directory record Official record
Conditions
Healthy Adult Female Participants
Interventions
Ensitrelvir
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 9, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

NCT07074327
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407, LNG/EE, NGM/EE, NET/EE, DRSP/EE
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 9, 2026, 1:54 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Renal Impairment Study for PF-06651600

NCT04037865
View directory record Official record
Conditions
Renal Impairment
Interventions
PF-06651600
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Miami, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 9, 2026, 1:54 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years

NCT07413666
View directory record Official record
Conditions
Healthy Adult Male and Female Volunteers
Interventions
ORX489 Tablets, Placebo Tablets
Drug · Other
Lead sponsor
Centessa Pharmaceuticals (UK) Limited
Industry
Eligibility
18 Years to 60 Years
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 9, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study To Estimate The Effect of PF-06650833 On The Pharmacokinetics (PK) of Oral Contraceptive (OC)

NCT05064332
View directory record Official record
Conditions
Healthy
Interventions
PF-06650833, Ethinyl estradiol (EE) and levonogestrel (LN)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 9, 2026, 1:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Proteomics of Cerebrospinal Fluid in Chronic Fatigue Syndrome

NCT00810329
View directory record Official record
Conditions
Chronic Fatigue Syndrome, Fibromyalgia, Gulf War Illness, Multiple Chemical Sensitivity, Interstitial Cystitis, Irritable Bowel Syndrome
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
21 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 25, 2014 · Synced Oct 9, 2026, 1:54 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Direct to Patient Minimal Risk Biospecimen and Data Collection Research

NCT07128966
View directory record Official record
Conditions
Healthy, Lupus, Celiac, Kidney Disease, Chronic, Dermatologic
Interventions
Observation
Other
Lead sponsor
Joined Bio
Industry
Eligibility
18 Years to 90 Years
Enrollment
100,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2036
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 9, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3819469 in Participants With Impaired and Normal Renal Function

NCT05841277
View directory record Official record
Conditions
Renal Insufficiency, Healthy
Interventions
LY3819469
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 9, 2026, 1:54 PM EDT
Not yet recruiting Phase 1 Interventional

A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)

NCT07848295
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions
BMS-986527, Nivolumab, Cabozantinib
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
6
States / cities
New Haven, Connecticut • Basking Ridge, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 9, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy Participants

NCT06368986
View directory record Official record
Conditions
HIV Infections
Interventions
VH4011499 Dose A, VH4011499 Dose B
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 9, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Bioavailability, Safety and Tolerability of a Solid Dosage Formulation Relative to a Suspension of JNJ-54175446 in Healthy Male and Female Participants

NCT02930694
View directory record Official record
Conditions
Healthy
Interventions
JNJ-54175446 (capsule), JNJ-54175446 (suspension)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Oct 9, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age

NCT06222892
View directory record Official record
Conditions
Cough
Interventions
Camlipixant
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 9, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants

NCT07378865
View directory record Official record
Conditions
Pain
Interventions
Suzetrigine
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 9, 2026, 1:54 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants

NCT06476834
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Deucravacitinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 9, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.

NCT05505162
View directory record Official record
Conditions
Healthy Female Participants
Interventions
Zibotentan, EE/LNG
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 9, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of [14C]-GDC-0810 After Single Oral Administration in Healthy Female Participants

NCT02802670
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-GDC-0810
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 9, 2026, 1:54 PM EDT
Completed Phase 1 Interventional

A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems

NCT06692322
View directory record Official record
Conditions
Liver Diseases, Healthy
Interventions
Zongertinib (BI 1810631)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 9, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Potential of Mavorixafor

NCT06914869
View directory record Official record
Conditions
Healthy Participants
Interventions
Mavorixafor, Carbamazepine, Efavirenz
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 9, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetic, Safety, Tolerability and Relative Bioavailability of Gepotidacin in Healthy Adult Male and Female Participants

NCT05271799
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Gepotidacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 9, 2026, 1:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exercise Dosing for Pain in Healthy Participants

NCT03642938
View directory record Official record
Conditions
Pain
Interventions
Walking Exercise, Control
Behavioral
Lead sponsor
Duquesne University
Other
Eligibility
18 Years to 40 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 9, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants

NCT05351892
View directory record Official record
Conditions
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes, Healthy Volunteers
Interventions
Elinzanetant (BAY3427080)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 9, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study in Healthy Participants to Assess the Effect of Rifampin on the Pharmacokinetics of JNJ-42847922

NCT02661893
View directory record Official record
Conditions
Healthy
Interventions
JNJ-42847922, Rifampin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 9, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants

NCT04016753
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986256, Loestrin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 40 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 9, 2026, 1:54 PM EDT